Savolitinib
Information
- Drug Name
- Savolitinib
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung non-small cell carcinoma |
MET p.Asp1246Val (p.D1246V) ( ENST00000318493.11, ENST00000397752.8 ) MET p.Asp1246Val (p.D1246V) ( ENST00000318493.11, ENST00000397752.8 ) |
C |
Predictive
|
Supports
|
Resistance | Somatic | 4 | 27694386 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Case report of a patient with lung adenocarcinoma ... | MET |
MET p.Asp1246Val (p.D1246V) ( ENST00000318493.11, ENST00000397752.8 ) MET p.Asp1246Val (p.D1246V) ( ENST00000318493.11, ENST00000397752.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03833440 | Active, not recruiting | Phase 2 | Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance | October 8, 2019 | February 2025 |
| NCT02761057 | Active, not recruiting | Phase 2 | Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed | July 25, 2016 | December 12, 2024 |
| NCT02819596 | Active, not recruiting | Phase 2 | MEDI4736 Combinations in Metastatic Renal Cell Carcinoma | January 2017 | March 2023 |
| NCT05163249 | Active, not recruiting | Phase 2 | Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC | May 31, 2022 | August 2026 |
| NCT03091192 | Active, not recruiting | Phase 3 | Savolitinib vs. Sunitinib in MET-driven PRCC. | July 25, 2017 | December 31, 2024 |
| NCT03385655 | Active, not recruiting | Phase 2 | Prostate Cancer Biomarker Enrichment and Treatment Selection | August 1, 2018 | December 31, 2025 |
| NCT03944772 | Active, not recruiting | Phase 2 | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | June 25, 2019 | May 6, 2025 |
| NCT02117167 | Completed | Phase 2 | SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | April 23, 2014 | December 2023 |
| NCT04118842 | Completed | Phase 1 | A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin | October 17, 2019 | February 26, 2020 |
| NCT04121910 | Completed | Phase 1 | A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole | November 7, 2019 | January 12, 2020 |
| NCT04179071 | Completed | Phase 1 | A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine | December 13, 2019 | March 11, 2020 |
| NCT04187456 | Completed | Phase 1 | A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body | December 27, 2019 | March 6, 2020 |
| NCT05768360 | Completed | Phase 1 | A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects | April 25, 2023 | June 24, 2023 |
| NCT05888207 | Completed | Phase 1 | A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects | June 2, 2023 | August 17, 2023 |
| NCT06348355 | Recruiting | Phase 1 | A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers | April 12, 2024 | June 28, 2024 |
| NCT04923932 | Recruiting | Phase 2 | Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients | July 27, 2021 | October 2025 |
| NCT04923945 | Recruiting | Phase 3 | Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients | August 19, 2021 | December 2024 |
| NCT05009836 | Recruiting | Phase 3 | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC | September 6, 2021 | January 31, 2025 |
| NCT05043090 | Recruiting | Phase 3 | Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC | October 28, 2021 | September 14, 2026 |
| NCT03598244 | Recruiting | Phase 1 | Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors | November 27, 2018 | January 31, 2025 |
| NCT05620628 | Recruiting | Phase 2 | Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) | January 5, 2023 | December 2025 |
| NCT05777278 | Recruiting | Phase 1/Phase 2 | Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression | July 26, 2023 | August 31, 2027 |
| NCT05261399 | Recruiting | Phase 3 | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment | August 3, 2022 | December 17, 2026 |
| NCT03778229 | Recruiting | Phase 2 | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | January 9, 2019 | May 28, 2025 |
| NCT05374603 | Suspended | Phase 2 | Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC | November 23, 2022 | December 31, 2024 |
| NCT03592641 | Terminated | Phase 2 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | July 25, 2019 | December 30, 2021 |
| NCT02897479 | Unknown status | Phase 2 | A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer | December 2016 | December 30, 2021 |